adcld-cov19
VaccineexperimentalCOVID-19
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Dec 29, 2020 (NCT04666012)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05993325 | Phase 3 | Sep 30, 2023 | Cellid Co., Ltd. |
| NCT05576623 | Phase 1/Phase 2 (Phase 2) | Sep 14, 2022 | Cellid Co., Ltd. |
| NCT05520970 | Phase 2 | Aug 31, 2022 | Cellid Co., Ltd., International Vaccine Institute |
| NCT05047692 | Phase 1 | Sep 9, 2021 | Cellid Co., Ltd. |
| NCT04666012 | Phase 1/Phase 2 (Phase 2) | Dec 29, 2020 | Cellid Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cellid Co., Ltd. | For profit | 5 | 4 | 3 | 2020 |
| International Vaccine Institute | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1